Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack,stroke or major bleed

Abstract

Objective:

To determine the direct healthcare costs associated with the onset of chronic nonvalvular atrial fibrillation (CNVAF), warfarin utilization and the occurrence of cerebrovascular events in a commercially-insured population.     

The effects of statin on atrial fibrillation: a meta-analysis of published data from randomized controlled trials

Abstract

Background:

Some clinical and experimental studies have shown the use of statins could protect against AF, but there are not adequate data at present.     

Presentation of atrial fibrillation and its management by cardiologists in the ambulatory and hospital setting: MOVE cross-sectional study

Abstract

Objective:

The aim of the study was to collect comprehensive data on atrial fibrillation (AF) in ambulatory and hospital-based management in Germany.     

Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification

Abstract

Background and objective:

Dabigatran is a new oral anticoagulant recently approved for the prevention of stroke or systemic embolism in patients with atrial fibrillation (AF). Based on its pharmacokinetic profile, dabigatran is dosed twice daily. This analysis provides a quantitative rationale for the selection of the dose regimen in this population.     

Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records

Abstract

Objective:

Automated electronic queries of structured data fields in electronic medical records (EMR) found no barriers to warfarin in 42% of patients with atrial fibrillation or atrial flutter (AF) with moderate or high risk of stroke and no warfarin. A thorough manual review of records (including text reports) from the same EMR may better identify physicians’ reasons for not using warfarin.     

Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy

Abstract

Objective:

Rhythm- and rate-control therapies are an essential part of atrial fibrillation (AF) management; however, the use of existing agents is often limited by the occurrence of adverse events. The aim of this study was to evaluate suspected adverse events and adverse event monitoring, and associated medical costs, in patients receiving AF rhythm-control and/or rate-control therapy.     

Safety,tolerability, pharmacokinetics and pharmacodynamics of albiglutide,a long-acting GLP-1-receptor agonist,in Japanese subjects with type 2 diabetes mellitus

Abstract

Objective:

To investigate safety, pharmacokinetics and pharmacodynamics of albiglutide in Japanese subjects with type 2 diabetes mellitus.     

Efficacy,safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension

Abstract

Objective:

To investigate the efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension (PAH).     

Comparison of safety outcomes among Caucasian,Hispanic, Black,and Asian patients in duloxetine studies of chronic painful conditions

Abstract

Objective:

This post-hoc analysis was conducted to investigate if safety outcomes differed among race/ethnic subgroups of patients treated with duloxetine for chronic painful conditions.     

Non-clinical pharmacology,pharmacokinetics, and safety findings for the antihistamine bepotastine besilate

Abstract

Scope:

The purpose of this review is to examine published non-clinical literature on the antihistamine bepotastine besilate, including pharmacokinetic and pharmacologic properties.     

Prevention of episodic migraine with topiramate: a prospective 24-week,open-label,flexible-dose clinical trial with optional 24 weeks follow-up in a community setting

Abstract

Objective:

To explore efficacy and safety outcomes of topiramate for episodic migraine prevention in community practice.     

Relationship between background cancer pain,breakthrough pain,and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies

Abstract

Background:

The different operational definitions of breakthrough cancer pain (BTcP) has generated unclear epidemiological data.     

Long-term safety,tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms

Abstract

Objective:

To evaluate long-term safety, tolerability, and efficacy of fesoterodine for men and women with overactive bladder (OAB) symptoms.     

Further assessment of the clinically effective dose range of etoricoxib: a randomized,double-blinded,placebo-controlled trial in rheumatoid arthritis

Abstract

Objective:

To further assess the clinically active dose range of etoricoxib, a COX-2 selective inhibitor, in rheumatoid arthritis (RA).     

Attention deficit hyperactivity disorder in the European adult population: prevalence,disease awareness,and treatment guidelines

Abstract

Background:

Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobiological disorder with childhood onset and persistence into adolescence and adulthood.     

Association between hypoglycemia and inpatient mortality and length of hospital stay in hospitalized,insulin-treated patients

Abstract

Objective:

To assess the impact of hypoglycemia on clinical outcomes among hospitalized, insulin-treated patients.     

Retrospective real-world comparison of medical visits,costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia

Abstract

Objective:

To compare healthcare resource utilization, costs, and treatment adherence associated with dasatinib versus nilotinib treatment as second-line therapies in chronic myeloid leukemia (CML) patients.     

Progression to type 2 diabetes,healthcare utilization,and cost among pre-diabetic patients with or without comorbid hypertension

Abstract

Objective:

This study examined progression to type 2 diabetes and compared healthcare utilization and costs among patients with pre-diabetes, with or without comorbid hypertension.     

Average daily dose,medication adherence,and healthcare costs among commercially-insured patients with fibromyalgia treated with duloxetine

Abstract

Objective:

What is the relationship between average daily dose (ADD) of duloxetine, adherence to therapy, and healthcare costs among patients with fibromyalgia?     

A 26-week,placebo- and pioglitazone-controlled,dose-ranging study of rivoglitazone,a novel thiazolidinedione for the treatment of type 2 diabetes

Abstract

Objective:

To examine the efficacy and general safety of rivoglitazone, a novel thiazolidinedione, as a treatment for type 2 diabetes in a dose-ranging study over a period of up to 6 months.